(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.78%) $83.20
(1.25%) $1.947
(-0.24%) $2 341.60
(0.20%) $27.59
(0.73%) $928.80
(-0.26%) $0.932
(-0.29%) $10.99
(-0.35%) $0.798
(0.25%) $92.11
Live Chart Being Loaded With Signals
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases...
Stats | |
---|---|
今日成交量 | 28 356.00 |
平均成交量 | 15 071.00 |
市值 | 2.67M |
EPS | $0 ( 2024-04-01 ) |
下一个收益日期 | ( $-0.940 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0600 |
ATR14 | $0.0740 (1.35%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-27 | Fraser Craig | Buy | 2 500 | Common Stock |
2023-09-26 | Fraser Craig | Buy | 2 500 | Common Stock |
2023-08-24 | Mcandrew Jamie | Sell | 0 | Common Stock |
2023-08-24 | Mcandrew Jamie | Buy | 0 | Common Stock |
2023-08-24 | Mcandrew Jamie | Sell | 220 | Employee Stock Option (Right to Buy) |
INSIDER POWER |
---|
36.21 |
Last 96 transactions |
Buy: 7 918 771 | Sell: 11 081 644 |
Windtree Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-82 000.00 (0.00 %) |
EPS: | $-94.23 |
FY | 2023 |
营收: | $0 |
毛利润: | $-82 000.00 (0.00 %) |
EPS: | $-94.23 |
FY | 2022 |
营收: | $0 |
毛利润: | $-1.06M (0.00 %) |
EPS: | $-62.23 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.73 |
Financial Reports:
No articles found.
Windtree Therapeutics Inc
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。